Journal article · 2025 · Open access
OP0065 Cancer Risk in Patients with Rheumatoid Arthritis Receiving Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Data from a Multicenter National Real-World Registry
Annals of the Rheumatic Diseases, 84, 57–59 · Published 1 June 2025 · DOI 10.1016/j.ard.2025.05.088
In brief
“OP0065 Cancer Risk in Patients with Rheumatoid Arthritis Receiving Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Data from a Multicenter National Real-World Registry” is a 2025 journal article by J. Molina Collada and 17 co-authors, published in Annals of the Rheumatic Diseases. OpenAlex counts 2 citations as of 19 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Annals of the Rheumatic Diseases.
- Citations
- 2
- Most cited in
- 2025 (2)
- Authors
- 18
Abstract
Background: Safety data on the use of biologic and targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) in patients with rheumatoid arthritis (RA) are reassuring. However, results from the ORAL Surveillance clinical trial have raised some concerns about a potential increase in cancer risk with the use of janus kinase inhibitors (JAKi) compared to tumour necrosis factor inhibitors (TNFi). Limited real-world data have not confirmed a higher increase in cancer risk except for non-melanoma skin cancer [1], but additional evidence comparing all available treatment options with longer exposure is needed. Objectives: To evaluate the risk of cancer in patients with RA receiving bDMARDs and tsDMARDs. Methods: Prospective cohort study from a multicenter national registry of targeted therapies, including RA patients treated with bDMARDs or tsDMARDs from 2000 to 2023. Patients with prior cancer were excluded from the analysis. Incidence rates (IR) were analysed, and adjusted and stratified Cox regression was used to estimate hazard ratios (HR) for all cancers excluding non-melanoma skin cancer (NMSC) and for NMSC. Treatment with TNFi was used as the reference for comparison. Results: Out of a total of 4,635 RA patients (mean age at disease onset 55.5 years, 79% female, median follow-up 3.6 years), 187 incident cancers were detected. Demographics and clinical variables of the patients are shown in Table 1. The standardized IR of cancer excluding NMSC per 1,000 patient-years was 7.8 for TNFi, 12 for IL6i, 9.2 for CD20i, 10.2 for JAKi, and 14.7 for CTLA4-A. The adjusted overall HR (95% CI) for cancer excluding NMSC compared to TNFi was 1.1 (0.8–1.6) for IL6i, 0.8 (0.5–1.4) for CD20i, 1.2 (0.8–1.8) for JAKi, and 1.1 (0.8–1.6) for CTLA4-A. The adjusted overall HR (95% CI) for NMSC compared to TNFi was 0.5 (0.2–1.5) for IL6i, 0.6 (0.2–1.8) for CD20i, 0.6 (0.2–2) for JAKi, and 1.1 (0.5–2.6) for CTLA4-A. No excess cancer risk was observed in the adjusted HR based on cardiovascular risk and line of treatment, neither for the group of all cancers excluding NMSC nor for NMSC (Figure 1). Conclusion: Based on the treatment patterns for RA patients observed in our real-world registry, we have not identified an increased cancer risk for any of the bDMARDs or tsDMARDs, in comparison to TNFi. REFERENCES: [1] Huss V, Bower H, Hellgren K, et al. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study. Ann Rheum Dis 2023;82:911–919. Figure 1Cancer risk excluding NMSC (A) and NMSC risk (B) (overall, stratified by cardiovascular risk and by…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Collada, J. M., Otero-Varela, L., Vela, P., Arija, S. M., Erausquin, C., Fernández, C. C., Ruíz, F. J. M., Calvo-Gutiérrez, J., Expósito, L., García-González, J. A., Ruiz-Montesinos, D., Rabadán, E., Mera-Varela, A. J., Ros, I., Colazo-Burlato, M., Plasencia‐Rodríguez, C., Sánchez‐Alonso, F., & Castrejón, I. (2025). OP0065 Cancer Risk in Patients with Rheumatoid Arthritis Receiving Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Data from a Multicenter National Real-World Registry. Annals of the Rheumatic Diseases, 84, 57–59. https://doi.org/10.1016/j.ard.2025.05.088
MLA 9
Collada, J. Molina, et al. “OP0065 Cancer Risk in Patients with Rheumatoid Arthritis Receiving Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Data from a Multicenter National Real-World Registry.” Annals of the Rheumatic Diseases, vol. 84, 2025, pp. 57–59. https://doi.org/10.1016/j.ard.2025.05.088.
Chicago
Collada, J. Molina, Lucía Otero-Varela, Paloma Vela, Sara Manrique Arija, Celia Erausquin, Cristina Campos Fernández, Francisco Javier Manero Ruíz, et al. 2025. “OP0065 Cancer Risk in Patients with Rheumatoid Arthritis Receiving Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Data from a Multicenter National Real-World Registry.” Annals of the Rheumatic Diseases 84: 57–59. https://doi.org/10.1016/j.ard.2025.05.088.
Harvard
Collada, J. M. et al. (2025) ‘OP0065 Cancer Risk in Patients with Rheumatoid Arthritis Receiving Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Data from a Multicenter National Real-World Registry’, Annals of the Rheumatic Diseases, 84, pp. 57–59. doi:10.1016/j.ard.2025.05.088.
IEEE
J. M. Collada et al., “OP0065 Cancer Risk in Patients with Rheumatoid Arthritis Receiving Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Data from a Multicenter National Real-World Registry,” Annals of the Rheumatic Diseases, vol. 84, pp. 57–59, 2025, doi: 10.1016/j.ard.2025.05.088.
BibTeX
@article{collada2025cancer,
title = {{OP0065 Cancer Risk in Patients with Rheumatoid Arthritis Receiving Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Data from a Multicenter National Real-World Registry}},
author = {Collada, J. Molina and Otero-Varela, Lucía and Vela, Paloma and Arija, Sara Manrique and Erausquin, Celia and Fernández, Cristina Campos and Ruíz, Francisco Javier Manero and Calvo-Gutiérrez, J. and Expósito, Lorena and García-González, J. A. and Ruiz-Montesinos, D. and Rabadán, Elena and Mera-Varela, A. J. and Ros, Inmaculada and Colazo-Burlato, María and Plasencia‐Rodríguez, Chamaida and Sánchez‐Alonso, Fernando and Castrejón, Isabel},
journal = {Annals of the Rheumatic Diseases},
year = {2025},
volume = {84},
pages = {57--59},
doi = {10.1016/j.ard.2025.05.088},
url = {https://doi.org/10.1016/j.ard.2025.05.088}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- rheumatoid arthritis
- cancer risk
- biologic DMARDs
- targeted synthetic DMARDs
- JAK inhibitors
- IL-6 inhibitors
- tumor necrosis factor inhibitors
- non-melanoma skin cancer
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Collada, J. M., Otero-Varela, L., Vela, P., Arija, S. M., Erausquin, C., Fernández, C. C., Ruíz, F. J. M., Calvo-Gutiérrez, J., Expósito, L., García-González, J. A., Ruiz-Montesinos, D., Rabadán, E., Mera-Varela, A. J., Ros, I., Colazo-Burlato, M., Plasencia‐Rodríguez, C., Sánchez‐Alonso, F., & Castrejón, I. (2025). OP0065 Cancer Risk in Patients with Rheumatoid Arthritis Receiving Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Data from a Multicenter National Real-World Registry. Annals of the Rheumatic Diseases, 84, 57–59. https://doi.org/10.1016/j.ard.2025.05.088
How many times has this paper been cited?
2 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Annals of the Rheumatic Diseases: sign in and open the full text from this page.
Who wrote this paper?
J. Molina Collada, Lucía Otero-Varela, Paloma Vela, Sara Manrique Arija, Celia Erausquin, Cristina Campos Fernández, Francisco Javier Manero Ruíz, J. Calvo-Gutiérrez, Lorena Expósito, J. A. García-González, D. Ruiz-Montesinos, Elena Rabadán and 6 more.
What is the DOI of this paper?
10.1016/j.ard.2025.05.088, permanently at https://doi.org/10.1016/j.ard.2025.05.088. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.